Pfizer terminates hemophilia A gene therapy deal with Sangamo; milestone payments lost

SANGAMO THERAPEUTICS, INC

Pfizer notified Sangamo of termination for convenience effective April 21, 2025; no BLA or MAA to be submitted.
Sangamo forfeits up to $220M in remaining milestones and all future royalties (14-20% of net sales).
Sangamo receives exclusive license back to develop and commercialize SB-525; Pfizer gets low single digit royalties.
Sangamo plans to seek a new partner to advance regulatory filings for giroctocogene fitelparvovec.
Pfizer had paid $125M already ($70M upfront + $55M milestones); remaining program rights revert.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.